Company intelligence / Profile preview

Barson

New Mexico, United States

Ownership: Private
Development stage: Other

Overview

Mercury Bio’s yEV™ platform has demonstrated cell-specific delivery for proteins, nucleic acids, and small molecules; Frame Bio is developing mRNA-based therapies for skin-bone axis indications.

Therapeutic areas: OncologyInfectious DiseasesDermatologyRheumatology
Modalities: Extracellular vesicle-based therapymRNA-based drugsSmall moleculeProteinNucleic acidBioceramics
Industry: Investors

Partnerships

Collaborative research agreements (HIMED + Mercury Bio, Frame Bio)

Beyond the preview

Go deeper on Barson.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Barson.

Explore the full profile